Ellen Scordino focuses on patent and trade secret litigation and client counseling in the pharmaceuticals, biologics, diagnostics, biofuels, and medical device industries but has also represented clients in a wide range of other patent and general commercial matters in courts across the country and in arbitrations.
She has particular expertise with Hatch-Waxman and BPCIA litigations and has led trial teams in obtaining favorable judgments and settlements in district courts and inter partes review proceedings. Scordino has also worked extensively with clients to create patent and litigation strategies mindful of regulatory issues and the FDA. She has litigated and counseled clients on matters involving blockbuster drugs, biologics and biosimilars, orphan drugs, PCR technologies, recombinant DNA technologies, medical devices, cannabis, biofuels, and chemistry (including food and consumer good additives).
- J.D., Fordham University School of Law
- B.S., Chemistry , Trinity College
- Massachusetts Lawyers Weekly: Top Women of Law
- Boston Business Journal: 40 Under 40
- The Legal 500 United States
2021 - Recommended, Patent Litigation: Full Coverage
Clients say, "Susan Krumplitsch and Ellen Scordino were valuable team members. Their responsiveness and excellent communication skills along with their flexibility made managing a complex dispute easy."
- Co-Author, "AI Inventorship Decision Leaves Open Questions," Law360, September 17, 2021
Earlier in her career, Ellen was a research scientist and chemist.
Memberships And Affiliations
- American Bar Association
- New York Intellectual Property Law Association
- Women in Bio
- Women in Law Empowerment Forum (WILEF) – Global Advisory Board member and Boston Co-Chair
My latest insights
Can an AI system be named the inventor? In wake of EDVA decision, questions remain
22 September 2021 .15 minute read